Zai Lab (09688) saw its shares climb more than 5% in late trading. At the time of writing, the stock was up 4.89% to HK$16.1, with a turnover of HK$247 million.

The move follows the company's recent announcement that the U.S. FDA has granted Fast Track designation to zocilurtatug pelitecan (zoci, formerly known as ZL-1310), an antibody-drug conjugate (ADC) targeting Delta-like ligand 3 (DLL3) with first-in-class potential. The designation is for the treatment of extrapulmonary neuroendocrine carcinomas (epNECs) in patients who have experienced disease progression following first-line standard therapy.

Previously, in May 2025, zoci received FDA Fast Track designation for the treatment of extensive-stage small cell lung cancer (ES-SCLC).

Separately, Zai Lab's partner argenx recently announced that the U.S. FDA has approved label expansions for VYVGART (efgartigimod alfa intravenous infusion) and VYVGART Hytrulo (efgartigimod alfa subcutaneous injection) for the treatment of all adult patients with generalized myasthenia gravis (gMG). Zai Lab secured the rights to efgartigimod in Greater China in January 2021.